Millennium Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Millennium Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.54M	Buy	22,800 +21,200	+1,325%	+$7.21M	﹤0.01%	2469
2025 Q4	$636K	Sell	1,600 -300	-16%	-$133K	﹤0.01%	4792
2025 Q3	$866K	Buy	1,900 +400	+27%	+$163K	﹤0.01%	4724
2025 Q2	$489K	Sell	1,500 -7,000	-82%	-$1.94M	﹤0.01%	4929
2025 Q1	$2.3M	Sell	8,500 -4,800	-36%	-$1.23M	﹤0.01%	3658
2024 Q4	$3.13M	Sell	13,300 -3,400	-20%	-$894K	﹤0.01%	3265
2024 Q3	$4.59M	Buy	+16,700	New	+$4.35M	﹤0.01%	2916
2024 Q2	–	Sell	-4,500	Closed	-$673K	–	5832
2024 Q1	$673K	Buy	+4,500	New	+$751K	﹤0.01%	4609
2023 Q4	–	Sell	-8,700	Closed	-$1.54M	–	6033
2023 Q3	$1.54M	Sell	8,700 -56,500	-87%	-$10.8M	﹤0.01%	3814
2023 Q2	$12.4M	Buy	+65,200	New	+$12.9M	0.01%	1806
2022 Q1	–	Sell	-9,500	Closed	-$1.61M	–	6851
2021 Q4	$1.61M	Buy	+9,500	New	+$1.77M	﹤0.01%	3962
2016 Q1	–	Sell	-50,000	Closed	-$4.71M	–	3233
2015 Q4	$4.71M	Buy	+50,000	New	+$4.64M	0.01%	1402
2015 Q2	–	Sell	-200,000	Closed	-$20.9M	–	3282
2015 Q1	$20.9M	Buy	+200,000	New	+$20.3M	0.04%	641
2014 Q3	–	Sell	-22,200	Closed	-$1.4M	–	3661
2014 Q2	$1.4M	Buy	+22,200	New	+$1.32M	﹤0.01%	1996
2014 Q1	–	Sell	-7,000	Closed	-$450K	–	3418
2013 Q4	$450K	Buy	+7,000	New	+$418K	﹤0.01%	2777

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management's ALNY Position: Q1 2026 in Review

Millennium Management increased its Alnylam Pharmaceuticals (ALNY) stake by 494% in Q1 2026, buying an estimated $127M and bringing the position to 447,887 shares worth $148M. The position accounts for 0.06% of the portfolio, ranked #300.

Millennium Management first reported a position in ALNY in Q3 2013 and has held it in 42 quarters since. The position peaked at $251M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Millennium Management held 447,887 shares of Alnylam Pharmaceuticals worth $148M as of Q1 2026.
Millennium Management bought 372,457 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $127M.
Alnylam Pharmaceuticals made up 0.06% of Millennium Management's portfolio in Q1 2026, its #300 holding.
Millennium Management first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 42 quarters since.
Millennium Management's Alnylam Pharmaceuticals position peaked at $251M in Q3 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.